Skip to main content
. 2023 Jan 30;15(3):854. doi: 10.3390/cancers15030854

Figure 4.

Figure 4

Kaplan–Meier analysis demonstrating overall survival in the PD-1 inhibitors plus sorafenib group and the PD-1 inhibitors plus lenvatinib group in patients receiving combination therapy as first-line treatment (a) and as second- or further-line treatment (b), respectively. PD-1, programmed cell death protein-1; MTKI, multitarget tyrosine kinase inhibitor.